AlphAIAlphAI — Financial news for AI agents
GlobeNewswireOCT 203 min read$PHAT

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

FLORHAM PARK, N.J., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- Phathom Pharmaceuticals, Inc. ( Nasdaq: PHAT ) , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on ...

Original reporting
GlobeNewswire · Phathom Pharmaceuticals
Published Oct 20, 2025, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025 — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

The upcoming earnings report is highly anticipated and could serve as a catalyst for stock movement.

02

Market read

The news is highly relevant for traders focusing on biotech and pharmaceutical sectors, especially those with exposure to gastrointestinal therapeutics.

03

What to watch

Market-wide volatility or sector-specific risks could overshadow company-specific news.

Timing: High, as the earnings report is scheduled for October 30, 2025.

Background

Phathom Pharmaceuticals specializes in gastrointestinal treatments and has shown recent positive clinical trial results.

Company-level read

Ticker impact

$PHATBullishMedium confidence
Context

High relevance due to upcoming financial results and positive sentiment.

Expected impact

Moderate upward movement expected post-earnings, with potential for short-term gains.

Evidence & confidence

The scheduled earnings release and bullish sentiment indicate a probable positive market reaction, but uncertainties around actual results and market conditions introduce moderate confidence.

Market effects

Sector

Positive sentiment could boost the gastrointestinal biopharmaceutical sector.

Regional

Primarily affecting US markets due to the company's US listing.

Global

Limited, as the news pertains to a single company with moderate relevance to global markets.

Counterpoint

What could challenge this read

Earnings may fall short of expectations, leading to a short-term decline.

Key entities

  • Company
    Phathom Pharmaceuticals

    A biopharmaceutical company focused on gastrointestinal diseases.

Read at source← All news

Related articles

SEP 29
$PHATMedAI 8/10

Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN…

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of

SEC EDGAR 8-K2 min
JUL 30
$PHATMed

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • ~1.7 million total VOQUEZNA ® prescriptions filled to date • Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026 • Q2 operatin

SEC EDGAR 8-K7 min
SEP 29
$LMTMedAI 8/10

Lockheed Martin (LMT) Secures $298 Million in New Defense Contra

Lockheed Martin (LMT) announced $298M in contract modifications for U.S. Navy and Japan's defense systems. The company offers a 2.63% dividend yield with a 50% payout ratio and 5.4% 3-year growth. Its GF Value suggests a 9.4% undervaluation. LMT has a GF Score of 89/100, with strong profitability and valuation metrics. Institutional guru ownership is robust, but insider activity shows net selling.

gurufocus.com2 min
SEP 29
$LMTMedAI 9/10

Lockheed Martin (LMT) Secures $245M Contract Modification to Exp

Lockheed Martin (LMT) received a $245M contract modification to expand production of F/A-18E/F Infrared Search and Track Block II systems for the U.S. Navy and Royal Australian Air Force. The company offers a 2.63% dividend yield, a 50% payout ratio, and a 3-year dividend growth rate of 5.4%. LMT's stock is trading 9.4% below its GF Value™ of $565.64, with a GF Score™ of 89/100. Institutional investors show mixed sentiment, while insiders have sold $4.0M in shares over the past year.

gurufocus.com2 min
SEP 29
$GMEMed

GameStop: Ryan Cohen reports 8.8% ownership stake

Ryan Cohen reported an 8.8% ownership stake in GameStop (GME), totaling 44,683,306 shares. He owns 40,948,522 shares directly, valued at $185,549,462, and 3,734,784 warrants received as a dividend. Cohen has sole voting and dispositive power over these shares, with no transactions since his last filing.

stocktitan.net1 min